Search

everythinglearnresearchcommunity

for

Search:↓

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

JAK inhibitors offer new hope for treating severe alopecia areata.

Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

Some alopecia treatments might help treat COVID-19, but more research is needed.

Many treatments for hair loss show potential, but more testing is needed to confirm their effectiveness. Only minoxidil for women and minoxidil and finasteride for men are FDA approved.

Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.

New drugs and combination therapies are improving treatment for lower urinary tract symptoms.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Severe alopecia areata patients have a low chance of spontaneous hair regrowth.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

New treatments and diagnostic methods for various animal skin conditions showed promising results.

New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.

Effective treatments for spinal and bulbar muscular atrophy are not yet available; more research is needed.

Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.

DrugNet effectively identifies new uses for existing drugs and may save resources in drug development.

Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.

The document concludes that pregnancy and cancer share immune evasion tactics, but more research is needed before using checkpoint blockade immunotherapy in pregnant cancer patients to avoid harm to the placenta.

New treatments for ichthyosis, like protein replacement and gene therapy, show promise and may become standard care.

Hidradenitis Suppurativa is likely an autoinflammatory disease, and better understanding its causes could improve treatments.

Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.